Drug class profile · refreshed daily from federal data

Leukotriene Receptor Antagonist

2 molecules in this class, $233.0M combined CY2024 Part D spend across 18.8M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Leukotriene Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $233.0Mcombined across class
Total Rx claims: 18.8M6.0M unique beneficiaries
Generic mfrs (active): 24across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Montelukast

Brand: SINGULAIR · 18.7M Part D claims (CY24) · 5.9M beneficiaries · First FDA approval: 2012-02-28

20 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.042

→

Avg plan cost$0.479

Part D spend $222.8M 11× spread, current vs floor

Class share

96%

of class CY24 spend

View profile →

Zafirlukast

100K Part D claims (CY24) · 29K beneficiaries · First FDA approval: 2010-11-18

4 generic mfrs 0 plans require PA

Low NADAC$0.541

→

Avg plan cost$0.622

Part D spend $10.2M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.